"Scientific work … must be done for itself, for the beauty of science." Marie Curie, chemist & physicist (1867 - 1934)

With licensing and collaboration now the lifeblood of the drug industry, the annual BIO-Europe get-together was focused on partnering. Nuala Moran was there.

Venture capital’s refusal to continue support helped Cyan Technology into liquidation. Rebuilt by its management, Cyan is now wary of asking VCs for money.

Some strange new ways of raising money are starting to emerge - but would-be borrowers and lenders are still making sense of them.

New regulations on the registration and testing of chemicals could have some problematic knock-on effects on European R&D – but they could also bring some lucrative work the way of contract research organisations.

Better, brighter, faster – that's where photonic lasers are trying to take us. A lay guide to the technology.

It has been six years since a French biotech company made a stock market debut – and now two, BioAlliance and ExonHit, are doing so. Is the European market reawakening?

Scientists are moving around as never before. And, argues Jean Guinet from the OECD, that’s not necessarily a bad thing.